Recent Updates
Recently added Catalysts
LRMR Positive Sentiment Score: 75/100

Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Thursday, December 18, 2025 1 min read
Key Takeaway: Larimar Therapeutics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. The presentation by the management team will take place on January 14 from 9:00 to 9:40 AM PST, followed by a 30-day replay available on their website. The company is focused on developing treatments for complex rare diseases, particularly its lead compound for Friedreich's ataxia.

Market Sentiment Analysis

POSITIVE FACTORS

  • Larimar Therapeutics is increasing visibility by presenting at a major healthcare conference.
  • The company's lead compound, nomlabofusp, targets a rare disease, showcasing their commitment to unmet medical needs.
  • Participation in 1x1 investor meetings indicates strong investor interest and potential for funding.

Full Press Release Details

BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12 – 15, 2026.
Details on the presentation can be found below.
Date: Wednesday, January 14, 2026
Time: 9:00 – 9:40 AM PST
Webcast Link: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317563-larimar-therapeutics-inc/webcast?gpu_only=true&kiosk=true
Following the conclusion of the presentation, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
jallaire@lifesciadvisors.com
Chief Financial Officer
mcelano@larimartx.com

Frequently Asked Questions

When is Larimar Therapeutics presenting at the J.P. Morgan Conference?

Larimar Therapeutics will present on January 14, 2026, from 9:00 – 9:40 AM PST.

Where can I watch the Larimar Therapeutics presentation?

The presentation can be watched via the webcast link provided on their event page.

How long will the presentation replay be available?

The replay of the presentation will be accessible for 30 days after the event.

What condition is Larimar's lead compound targeting?

Larimar's lead compound, nomlabofusp, is aimed at treating Friedreich's ataxia.

What is Larimar Therapeutics focused on developing?

Larimar Therapeutics focuses on treatments for complex rare diseases.

Tags: LRMR Viatris Investor Conferences Healthcare Larimar Therapeutics J.P. Morgan Healthcare Conference Friedreich's ataxia biotechnology
Last updated: Dec 18, 2025